tbuckley/cabot-search huggingface dataset:
Abstract 11677: The Complement Receptor C3aR1 is Required for Immune Cell Recruitment and Formation of Granulation Tissue During Neonatal Mouse Cardiac Regeneration
Authors: Shuoshuo Wang, Niranjana Natarajan, Anthony Zhu, Richard T Lee
Journal: Circulation (2021)

The adult human heart is unable to regenerate after a major injury, while some vertebrates including neonatal mice heart possess substantial heart regeneration. In a previous multi-species transcriptome study, we identified Complement receptors C5aR1 and C3aR1 as evolutionarily conserved upregulated genes during the early phase of heart regeneration in multiple species. The complement system is a central mechanism in innate immunity, but its role in heart regeneration is unclear. After apical resection in neonatal mice, we administrated Cobra Venom Factor (CVF) to specifically deplete Complement, and the mice failed to regenerate the injured myocardium after three weeks. At 2 days after injury, the size of the sagittal area across post-traumatic granulation tissue was significantly reduced by 62.6% (n=5 each, p&lt;0.05), suggesting that complement is necessary for myocardium regeneration through forming granulation tissue as a transient step. Furthermore, genetic deletion of the C3aR1 receptor (C3aR1-KO mice) phenotypically recapitulated the impaired myocardial regeneration observed in Complement-depleted animals. C3aR1 KO mice possessed significantly reduced number of Itgam + (Complement Receptor 3, CD11b) leukocytes, especially CD68 + cells of pan-monocyte lineage and failed to form granulation tissue at the injured apex. Noteworthy, both resected C3aR1-KO and CVF-treated mice shared a common pattern when compared to control animals: downregulation of cell-cycle regulators (e.g., Cdc20, PCNA-associated factor, Cyclin B2, Mcm5) and DNA-damage responders (Survivin, Rad51, Top2a). Since Cdc20 regulates cell-cycle progression and is tightly associated with cardiomyocytes undergoing complete cytokinesis, this is one candidate downstream effector for the complement response. Our results demonstrate that complement and C3aR1 activation is crucial for neonatal mouse cardiac regeneration by initiating rapid granulation tissue formation through immune cell recruitment.
Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant
Authors: Susan Prockop, Laurence Gamelin, Rajani Dinavahi, Yan Sun, Weizhi Zhao, Faith Galderisi, Aditi Mehta
Journal: Blood (2021)
Hospitalization and Healthcare Resource Use of Omidubicel Vs Cord Blood Transplantation for Hematological Malignancies in a Global Randomized Phase III Clinical Trial
Authors: Navneet S. Majhail, Beckley Miller, Rebecca Dean, Rocio Manghani, Smitha Sivaraman, Einat Galamidi-Cohen, Richard T. Maziarz
Journal: Blood (2021)
T-Cell Phenotype Varies in Distinct Tumor Microenvironments and CD57 + T FH Cells Are Associated with Disease Progression and Inferior Survival in Follicular Lymphoma
Authors: Zhi-Zhang Yang, Hyojin Kim, Hongyan Wu, Xinyi Tang, Jordan E. Krull, Jose Villasboas, Anne J. Novak, Stephen M. Ansell
Journal: Blood (2021)
Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome without Hematopoietic Cell Transplantation in a Real-World Population in the United States: Patient Characteristics, Prior Treatment Patterns, and Time to Diagnosis
Authors: Xue Wang, Bouchra Benettaib, Weiyi Ni, Harry Jin, Seth Kuranz, Vian Amber, Rami Ben-Joseph
Journal: Blood (2021)
Management of anastomotic leaks after elective colorectal resections: The East of England experience. A retrospective cohort
Authors: Medhat Aker, Alan Askari, Mohamed Rabie, Mohamed Aly, Samuel Adegbola, Krashna Patel, Chelise Currow, Rebecca Nunn, Christopher Hadjittofi, Adeline Rankin, Sonal Halai, Karim Elsamani, Sophie Bondje, Islam Mohamed, John Lee, Joshua Wong, Eve Robertson-Waters, Aaliya Uddin, James Hollingshead
Journal: International Journal of Surgery (2021)
Single-Cell Transcriptomic and Proteomic Analysis of Acute Myeloid Leukemia (AML) Patients with Abnormalities on Chromosome 7
Authors: Gege Gui, Meghali Goswami, Chidera Nosiri, Laura W. Dillon, Gabriel Ghiaur, Rena Xian, Pradeep Dagur, Philip McCoy, Christopher S. Hourigan
Journal: Blood (2021)
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
Authors: Adrienn Angyal, Stephanie Longet, Shona C Moore, Rebecca P Payne, Adam Harding, Tom Tipton, Patpong Rongkard, Mohammad Ali, Luisa M Hering, Naomi Meardon, James Austin, Rebecca Brown, Donal Skelly, Natalie Gillson, Sue L Dobson, Andrew Cross, Gurjinder Sandhar, Jonathan A Kilby, Jessica K Tyerman, Alexander R Nicols, Jarmila S Spegarova, Hema Mehta, Hailey Hornsby, Rachel Whitham, Christopher P Conlon, Katie Jeffery, Philip Goulder, John Frater, Christina Dold, Matthew Pace, Ane Ogbe, Helen Brown, M Azim Ansari, Emily Adland, Anthony Brown, Meera Chand, Adrian Shields, Philippa C Matthews, Susan Hopkins, Victoria Hall, William James, Sarah L Rowland-Jones, Paul Klenerman, Susanna Dunachie, Alex Richter, Christopher J A Duncan, Eleanor Barnes, Miles Carroll, Lance Turtle, Thushan I de Silva, Adam Harding, Adam Watson, Adrian Shields, Adrienn Angyal, Ahmed Alhussni, Alex Richter, Alexander Nicols, Alexandra Deeks, Alice Webb-Bridges, Andrew Cross, Ane Ogbe, Anni Jämsén, Anthony Brown, Anu Chawla, Christina Dold, Christopher Duncan, Christopher Conlon, Donal Skelly, Denise O'Donnell, Eleanor Barnes, Emily Adland, Esme Weeks, Gurjinder Sandhar, Hailey Hornsby, Helen Brown, Hema Mehta, Hibatullah Abuelgasim, Huiyuan Xiao, James Austin, Jarmila Spegarova, Jennifer Holmes, Jenny Haworth, Jessica Tyerman, John Frater, Jonathan Kilby, Joseph Cutteridge, Katie Jeffery, Katy Lillie, Lance Turtle, Leigh Romaniuk, Lucy Denly, Luisa Hering, M. Azim Ansari, Matthew Pace, Meera Chand, Miles Carroll, Mohammad Ali, Mwila Kasanyinga, Naomi Meardon, Natalie Gillson, Patpong Rongkard, Paul Klenerman, Philip Goulder, Philippa Matthews, Rachel Whitham, Rebecca Brown, Rebecca Payne, Robert Wilson, Sarah Rowland-Jones, Sarah Thomas, Shona Moore, Siobhan Gardiner, Stephanie Longet, Stephanie Tucker, Sue Dobson, Susan Hopkins, Susanna Dunachie, Syed Adlou, Thushan de Silva, Tom Tipton, Victoria Hall, William James, Allan Lawrie, Nikki Smith, Helena Turton, Amira Zawia, Martin Bayley, Alex Fairman, Kate Harrington, Rosemary Kirk, Louise Marsh, Lisa Watson, Steven Wood, Benjamin Diffey, Chris Jones, Lauren Lett, Gareth Platt, Krishanthi Subramaniam, Daniel Wootton, Brendan Payne, Sophie Hambleton, Sinead Kelly, Judith Marston, Sonia Poolan, Dianne Turner, Muzlifah Haniffa, Emily Stephenson, Sandra Adele, Hossain Delowar Akhter, Senthil Chinnakannan, Catherine de Lara, Timothy Donnison, Carl-Philipp Hackstein, Lian Lee, Nicholas Lim, Tom Malone, Eloise Phillips, Narayan Ramamurthy, Nichola Robinson, Oliver Sampson, David Eyre, Beatrice Simmons, Lizzie Stafford, Alexander Mentzer, Ali Amini, Carolina Arancibia-Cárcamo, Nicholas Provine, Simon Travis, Stavros Dimitriadis, Sile Johnson, Sarah Foulkes, Jameel Khawam, Edgar Wellington, Javier Gilbert-Jaramillo, Michael Knight, Maeva Dupont, Emily Horner, James Thaventhiran, Jeremy Chalk
Journal: The Lancet Microbe (2021)
Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma
Authors: Sham Mailankody, Michaela Liedtke, Surbhi Sidana, Jeffrey V. Matous, Saurabh Chhabra, Olalekan O. Oluwole, Shahbaz A. Malik, Shaji Kumar, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, Sundar Jagannath, Myo Htut, Noopur S. Raje, David S. Siegel, Erin E. Karski, Wade Lovelace, Afrodite Lourbakos, Srinand Ponnathapura Nandakumar, Arun Balakumaran, Parameswaran Hari
Journal: Blood (2021)
<i>Protein Phosphatase 6C (PPP6C) Loss Significantly Raises Fetal Hemoglobin Levels and Reduces Cell Sickling</i>
Authors: Scott A. Peslak, Eugene Khandros, Peng Huang, Maryanne Kihiu, Osheiza Abdulmalik, Cheryl A. Keller, Ross C. Hardison, Junwei Shi, Gerd A. Blobel
Journal: Blood (2021)
NEK2 Inhibition Enhances the Efficacy of PD-1/PD-L1 Blockade in Multiple Myeloma
Authors: Yan Cheng, Fumou Sun, Huojun Cao, Dongzheng Gai, Bailu Peng, Hongwei Xu, Frits van Rhee, Siegfried Janz, Guido Tricot, John D Shaughnessy, Fenghuang Zhan
Journal: Blood (2021)
An Open-Label Phase II Trial of the Combination of Decitabine, SQ Bortezomib and Pegylated Liposomal Doxorubicin for the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia
Authors: Laura A. Potter, Maria Galkin, Aaron S. Rosenberg, Rasmus T. Hoeg, Mehrdad Abedi, Joseph M. Tuscano, Brian A. Jonas
Journal: Blood (2021)
CD30-Directed CAR-T Cells Co-Expressing CCR4 in Relapsed/Refractory Hodgkin Lymphoma and CD30+ Cutaneous T Cell Lymphoma
Authors: Natalie S Grover, Anastasia Ivanova, Dominic T. Moore, Catherine Joyce Arago Cheng, Caroline Babinec, John West, Tammy Cavallo, J. Kaitlin Morrison, Faith Brianne Buchanan, Edith Bowers, Christopher Dittus, Anne W. Beaven, Gianpietro Dotti, Jonathan S. Serody, Barbara Savoldo
Journal: Blood (2021)
Medical Specialty Board Parental, Caregiver, and Medical Leave Policy Updates After 2021 American Board of Medical Specialties Mandate
Authors: Kirti Magudia, Shauna R. Campbell, Erika L. Rangel, Elizabeth Kagan Arleo, Reshma Jagsi, Debra F. Weinstein, Thomas S. C. Ng
Journal: JAMA (2021)

This study assesses how member boards of the American Board of Medical Specialties (ABMS) have adhered to a 2021 ABMS policy change allowing residents a minimum of 6 weeks of parental, caregiver, and medical leave.
Phase 3 Fracture Trial of Odanacatib for Osteoporosis - Study Design
Authors: H. Bone, D. Dempster, J.A. Eisman, S. Greenspan, M. McClung, T. Nakamura, S. Papapoulos, J. Shih, A. Lombardi, A. Santora, N. Verbruggen, E. Rosenberg, A. Leung
Journal: Endocrine Reviews (2010)
First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis
Authors: Tamer Othman, Juan Penaloza, Elizabeth A Brem, Lauren C. Pinter-Brown, Abinav Baweja, Matthew Hyun Joon Lee, Jane Ly, Jack Reid, Haifaa Abdulhaq, Daria Gaut, Caspian Oliai, Erin G. Reid, Joseph M Tuscano
Journal: Blood (2021)
Treatment and in-Hospital Overall Survival in Hematological Patients with Grade 4 Neutropenia and Coronavirus Infection
Authors: Ksenia V. Kaluzhskaya, Yuri Yu. Polyakov, Elena A. Baryakh, Eduard G. Gemdzhian, Elena N. Misyurina, Evgenia I. Zhelnova, Konstantin V. Yatskov, Olga L. Kochneva, Inna V. Samsonova, Mariana A. Lysenko, Diana D. Ivanova, Tatyana S. Chudnova, Denis A. Fedorenko
Journal: Blood (2021)
ADG152, a Novel CD20xCD3 T Cell Engager Prodrug with Enhanced Therapeutic Index, Demonstrates Strong Anti-Tumor Activity with Improved Safety
Authors: Bin Cai, Aaron N Nguyen, Songmao Zheng, Jianfeng Shi, Guizhong Liu, Yan Li, Felix Du, Stanley Frankel, Peter Luo, Jiangchun Xu
Journal: Blood (2021)
Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection
Authors: Laura M. Snell, Wenxi Xu, Diala Abd-Rabbo, Giselle Boukhaled, Mengdi Guo, Bethany L. Macleod, Heidi J. Elsaesser, Kebria Hezaveh, Nirmin Alsahafi, Sabelo Lukhele, Sara Nejat, Ramanandan Prabhakaran, Slava Epelman, Tracy L. McGaha, David G. Brooks
Journal: Nature Immunology (2021)
Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma
Authors: Makoto Yoshimitsu, Koji Izutsu, Shinichi Makita, Kisato Nosaka, Atae Utsunomiya, Shigeru Kusumoto, Satoko Morishima, Kunihiro Tsukasaki, Toyotaka Kawamata, Takaaki Ono, Shinya Rai, Hiroo Katsuya, Jun Ishikawa, Hironori Yamada, Kazunobu Kato, Masaya Tachibana, Yasuyuki Kakurai, Nobuaki Adachi, Kensei Tobinai, Kentaro Yonekura, Kenji Ishitsuka
Journal: Blood (2021)
Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial
Authors: Mahamadou S Sissoko, Sara A Healy, Abdoulaye Katile, Irfan Zaidi, Zonghui Hu, Bourama Kamate, Yacouba Samake, Kourane Sissoko, Agnes Mwakingwe-Omari, Jacquelyn Lane, Alemush Imeru, Rathy Mohan, Ismaila Thera, Cheick Oumar Guindo, Amagana Dolo, Karamoko Niare, Fanta Koïta, Amadou Niangaly, Kelly M Rausch, Amatigue Zeguime, Merepen A Guindo, Aissatou Bah, Yonas Abebe, Eric R James, Anita Manoj, Tooba Murshedkar, Natasha KC, B Kim Lee Sim, Peter F Billingsley, Thomas L Richie, Stephen L Hoffman, Ogobara Doumbo, Patrick E Duffy
Journal: The Lancet Infectious Diseases (2021)
Mitochondrial DNA Mutations Distinguish Individual Donor- and Recipient-Derived Immune Cells Following Matched Unrelated Allogeneic Stem Cell Transplantation
Authors: Livius Penter, Jackson Southard, Shuqiang Li, Caleb A. Lareau, Leif S. Ludwig, Nicoletta Cieri, Alexandria Maurer, Daniel J. DeAngelo, Srinika Ranasinghe, Donna S. Neuberg, Vijay G. Sankaran, Robert J. Soiffer, Kenneth J. Livak, Jacqueline S. Garcia, Catherine J. Wu
Journal: Blood (2021)
Follow-up Next Generation Sequencing (NGS) Analyses on Clonal Chronic Idiopathic Neutropenia (CIN) Patients: Insights in the Natural History of the Disease
Authors: Grigorios Tsaknakis, Stavros Papadakis, Peggy Kanellou, Irene Mavroudi, Irene Fragiadaki, Charalampos Pontikoglou, Anna Gallì, Luca Malcovati, Helen A. Papadaki
Journal: Blood (2021)
Outcomes of Haploidentical Salvage Transplantation Using Post-Transplant Cyclophosphamide for Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Kaito Harada, Shigeo Fuji, Yuho Najima, Motohiro Kato, Akihito Shinohara, Masako Toyosaki, Hirohisa Nakamae, Daisuke Hasegawa, Hiroatsu Iida, Makoto Onizuka, Yoshiko Hashii, Tatsuo Ichinohe, Yoshiko Atsuta, Hideki Nakasone
Journal: Blood (2021)
Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical <i>BCR-ABL1</i> Fusion Transcripts: The French CML Group (Fi-LMC) Experience
Authors: Hyacinthe Johnson-Ansah, Aude Charbonnier, Delphine Rea, Gabriel Etienne, Lydia Roy, Laurence Legros, Agnes Guerci Bresler, Anne Bouvier, Emilie Cayssials, Valerie Coiteux, Philippe Rousselot, Stephanie Dulucq, Sandrine Hayette, Francois-Xavier Mahon, Franck E. Nicolini
Journal: Blood (2021)
Partha Kar: Holding up a mirror to racism in the NHS
Authors: Partha Kar
Journal: BMJ (2021)

Listening to Azeem Rafiq's testimony to MPs about institutional racism at Yorkshire County Cricket Club, 1 it all rings true-and it burns.It burns to the core of your soul.What Rafiq has gone through could be the story of many an NHS doctor or nurse.The banter, the jokes, the sly comments, the racial slurs, the obstruction to career progression . . .they've been a constant presence during my career in the NHS.It's easy to brush these off as "sins of the past" or "throwbacks," as if the present healthcare system were immune to such things.But swathes of clinicians across the NHS will tell you that these things aren't old and that they haven't gone away.
AFM28, a Novel Bispecific Innate Cell Engager (ICE ®), Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Authors: Jana-Julia Götz, Jens Pahl, Nanni Schmitt, Thomas Müller, Torsten Haneke, Izabela Kozlowska, Séverine Sarlang, Stefan Knackmuss, Eike Peters, Uwe Reusch, Thorsten Ross, Daniel Nowak, Wolf-Karsten Hofmann, Christian Merz
Journal: Blood (2021)
Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study
Authors: Alexander Roeth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D'Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-Ichi Nishimura, Josephine M.I. Vos, Michael Storek, Nancy Wong, Parija Patel, Braydon Schaible, Xiaoyu Jiang, Deepthi Vagge, Marek Wardecki, Frank Shafer, Michelle Lee, Catherine M. Broome
Journal: Blood (2021)
510TiP Camrelizumab combined with fruquintinib or regorafenib as second or later line therapy for BRAF positive-mutation advanced colorectal cancer (CRC) with microsatellite stability (MSS): A single-arm, phase II study
Authors: X. Wei, Z. Li, Y. Han, H. Yuan, X. Du, K. Jin, W. Zhang, T. Zhang, H. Sui
Journal: Annals of Oncology (2021)
The Paradoxical Efficacy of KDM6 Inhibition in Germinal Centre B-Cell Lymphomas
Authors: Karina Close, Hannah Armes, Emil Kumar, Findlay Bewicke-Copley, Adam Cribbs, James Dunford, Martin Philpott, Udo Oppermann, James Heward, Jude Fitzgibbon
Journal: Blood (2021)
Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study
Authors: Franck Morschhauser, Mark Bishton, Toby A. Eyre, Emmanuel Bachy, Guillaume Cartron, Loïc Ysebaert, Sabela Bobillo, Norma C. Gutierrez, L. Elizabeth Budde, Christopher P. Fox, Andrea Knapp, Manejeh Yaqub, Michael C. Wei, Carol O'Hear, Haocheng Li, Enkhtsetseg Purev, William Townsend
Journal: Blood (2021)
Abstract 9386: Marfan Syndrome Mouse Model MgΔLpn Presents Alterations in Glomerular Architecture and Increased Renal Vascular Resistance. Losartan Treatment Attenuates These Phenotypes
Authors: Rodrigo Barbosa Souza, Dieter P. Reinhardt, Ivan H Koh, Lygia d Pereira
Journal: Circulation (2021)

Introduction: Previously, we have shown that mgΔlpn murine Marfan syndrome (MFS) model with a fibrillin-1 disruption presents increased Metalloproteinase-9 (MMP-9) expression in the cilliary body i...
Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Authors: Steven M. Horwitz, Tatyana A. Feldman, Jing C. Ye, Michael S. Khodadoust, Javier Munoz, Paul A. Hamlin, Youn H. Kim, Ryan A. Wilcox, Manish R. Patel, Greg P. Coffey, Muhtarjan Osman, Jaymes S Holland, Cristina B Guzman, Sonali M. Smith
Journal: Blood (2021)
30 Blood-based glycoprotein signatures in advanced non-small-cell lung carcinoma (NSCLC) receiving first-line immune checkpoint blockade
Authors: Klaus Lindpaintner, Michael Cheng, Jillian Prendergast, Karl Normington, Maurice Wong, Gege Xu, Xini Cong, Rachel Rice, Marissa Lawrence, Kesi Michael, Daniel Serie
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Immune checkpoint blockade is an integral component of first-line therapy for most patients with ad-vanced non-small cell lung cancer (NSCLC), however individual patient outcomes are highly variable and improved biomarkers are needed. Protein glycosylation is an emerging mechanism of immune evasion in cancer. We examined blood-based glycopeptide signatures in a cohort of advanced NSCLC patients treated with first-line immune checkpoint blockade. Methods Pretreatment blood samples were obtained from 46 advanced NSCLC patients treated with first line pembrolizumab or pembrolizumab + carboplatin + pemetrexed. All patients provided written in-formed consent to the institutional review board–approved protocols (#02–180 and 13–367) at the Da-na-Farber/Harvard Cancer Center (Boston, MA), and the study was conducted in accordance with the Declaration of Helsinki. Samples were analyzed using an advanced glycoproteomics platform (Inter-Venn Biosciences) that combines ultra-high-performance liquid chromatography coupled to triple quadrupole mass spectrometry with a proprietary neural-network-based data processing engine. 409 individual glycopeptide (GP) signatures derived from 67 abundant serum proteins were analyzed and correlated with overall survival (OS) and other clinical outcomes. Results We identified 30 GPs with abundance differences using a False Discovery Rate (FDR) threshold of 0.05. Using the 5 most predictive GP markers, we created a multivariable model for OS by generating leave-one-out cross-validation (LOOCV) scores and determining an optimized cutoff value of -0.83 (range: -2.2 - 3.4) for these scores using Harrell’s concordance index. The median overall survival was 2.8 years for patients (n=14) whose GP classifier value was above the cutoff and 0.8 years for patients (n=32) whose GP classifier value was below the cutoff (HR 7.4, 95% CI 1.7–32.1, p=0.007) The model’s perfor-mance was not affected by sex, age, or treatment regimen. Conclusions Blood-based glycopeptide signatures may represent novel, non-invasive biomarkers of clinical out-come to first-line immune checkpoint blockade in advanced NSCLC. Additional research is needed to validate these findings in larger cohorts and to explore potential applications relevant to clinical decision-making. Ethics Approval The study obtained ethics approval from the institutional review board (approved protocol #02–180 and 13–367) at the Dana-Farber/Harvard Cancer Center (Boston, MA), and the study was conducted in accordance with the Declaration of Helsinki. Consent All patients provided written informed consent to the institutional review board–approved protocols (#02–180 and 13–367) at the Dana-Farber/Harvard Cancer Center (Boston, MA), and the study was conducted in accordance with the Declaration of Helsinki.
A 15-Year Analysis of Surgical Resident Operative Autonomy Across All Surgical Specialties in Veterans Affairs Hospitals
Authors: Devashish J. Anjaria, Anastasia Kunac, Jamal L. McFarlane, Joseph B. Oliver
Journal: JAMA Surgery (2021)

This cross-sectional study uses data from the Veterans Affairs Surgical Quality Improvement Project to examine changes in the autonomy of resident physicians in the operating room over the past 15 years.
Understanding longevity in Hong Kong: a comparative study with long-living, high-income countries
Authors: Michael Y Ni, Vladimir Canudas-Romo, Jian Shi, Francis P Flores, Mathew S C Chow, Xiaoxin I Yao, Sai Yin Ho, Tai Hing Lam, C Mary Schooling, Alan D Lopez, Majid Ezzati, Gabriel M Leung
Journal: The Lancet Public Health (2021)